Analyst Price Targets — BLLN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| June 29, 2026 10:59 am | — | Guggenheim | $125.00 | $118.17 | TheFly | BillionToOne price target raised to $125 from $120 at Guggenheim |
| May 7, 2026 12:08 pm | — | BTIG | $130.00 | $82.83 | TheFly | BillionToOne price target lowered to $130 from $140 at BTIG |
| March 5, 2026 2:20 pm | Mark Massaro | BTIG | $140.00 | $72.66 | StreetInsider | BillionToOne Inc (BLLN) PT Lowered to $140 at BTIG |
| January 6, 2026 11:45 am | — | Guggenheim | $120.00 | $95.00 | TheFly | BillionToOne initiated with a Buy at Guggenheim |
| December 1, 2025 11:11 am | Mark Massaro | BTIG | $160.00 | $130.18 | TheFly | BillionToOne initiated with a Buy at BTIG |
| December 1, 2025 10:06 am | — | Wells Fargo | $110.00 | $130.18 | TheFly | BillionToOne initiated with an Equal Weight at Wells Fargo |
| December 1, 2025 9:41 am | — | Stifel Nicolaus | $145.00 | $130.18 | TheFly | BillionToOne initiated with a Buy at Stifel |
| December 1, 2025 7:45 am | David Westenberg | Piper Sandler | $150.00 | $130.18 | StreetInsider | Piper Sandler Starts BillionToOne Inc (BLLN) at Overweight |
| December 1, 2025 7:43 am | Tycho Peterson | Jefferies | $117.00 | $130.18 | StreetInsider | Jefferies Starts BillionToOne Inc (BLLN) at Hold |
Latest News for BLLN
MENLO PARK, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced that the Company plans to release its financial results for the second quarter ended June 30, 2026 after the market close on Wednesday, August 5, 2026. BillionToOne will host a…
According to a Form 4 filing, a BillionToOne executive sold 801 shares of Class A Common Stock at $124.91 per share for a total transaction value of $100,053 on July 1, 2026. The disposition reduced the insider's direct Class A common equity holdings by 4% in this transaction.
Tom Gardner makes the case for fifty-stock portfolios and AI-powered research, then names five companies to consider owning for the next five-plus years.
Here is how BillionToOne (BLLN) and Concentra Group (CON) have performed compared to their sector so far this year.
BillionToOne's Northstar Response Is a Stronger Predictor of Immunotherapy Outcomes Than Standard-of-Care Imaging for Cancer Patients in Peer
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for BLLN.
Senate Trading
No Senate trades found for BLLN.
U.S. House Trading
No House trades found for BLLN.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.